Essential Biochemistry for Medicine is not intended to be an exhaustive, comprehensive reference; rather a concise, accessible guide that will help first year students, from a wide spectrum of backgrounds, gain a good basic understanding of the biochemistry behind common medical disorders. It integrates biochemistry with clinical applications and the understanding of the etiology of diseases, their diagnosis and treatment. Each chapter includes a concise and simple introduction to the relevant biochemistry and terminology to reinforce what biomedical students have covered, orientate them and encourage them to consider the medical context; whilst at the same time outlining the biochemistry in a simple, must know format, for medical students before directing them to the all important clinical considerations.
Key Features: * A fully integrated approach to give students a basic understanding of the biochemistry behind common medical disorders * Concise, accessible and well-written with numerous clear illustrations in full colour throughout * Uses 'FOCUS' sections to expand on certain areas such as diabetes, HIV and obesity * Includes links and quick references for those wanting a broader knowledge of each topic
A New York Times bestseller. WINNER OF THE FINANCIAL TIMES/MCKINSEY BUSINESS BOOK OF THE YEAR AWARD 2018 The full inside story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup, by the prize-winning journalist who first broke the story and pursued it to the end, despite pressure from its charismatic CEO and threats by her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup unicorn promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. In Bad Blood, John Carreyrou tells the riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley. Now to be adapted into a film, with Jennifer Lawrence to star. 'Chilling . . . Reads like a West Coast version of All the President's Men.' New York Times Book Review